CELLECTIS SA Reaches 40th Meganuclease Milestone
Romainville, September 28, 2009 - Cellectis S.A. (Alternext : ALCLS), the leading French genome engineering company, announced today that it has delivered a new meganuclease to the Association Française contre les Myopathies (the French Muscular Dystrophy Association) - the 40th meganuclease engineered since the beginning of this year.
By constantly improving its meganucleases engineering processes, Cellectis has made a real breakthrough since January 2009 in the efficiency of its technology platform. This has resulted in a reduction in the time required to produce a new meganuclease and an increase in capacity, while further raising its quality and activity standards. This will allow Cellectis to speed up the set up of its strategy.
more information : www.cellectis.com
By constantly improving its meganucleases engineering processes, Cellectis has made a real breakthrough since January 2009 in the efficiency of its technology platform. This has resulted in a reduction in the time required to produce a new meganuclease and an increase in capacity, while further raising its quality and activity standards. This will allow Cellectis to speed up the set up of its strategy.
more information : www.cellectis.com